| Carla Coffin |  | University of Calgary | Canada | C Coffin_New guidelines and Re-Thinking HBV Nomenclature for Therapeutic Endpoints.pdf |
| David Brooks |  | Princess Margaret Cancer Center | Canada | D Brooks_High dimensional analysis for immune correlates of therapeutic response and biomarker discovery.pdf |
| Fabien Zoulim |  | Lyon University | France | F Zoulim_Editing and Epigenome editing of HBV Current knowledge on efficacy and risks.pdf |
| Pietro Lampertico |  | University of Milan | Italy | P Lampertico_Advances in HDV treatment Bulevirtide vs. mAb vs. small molecule.pdf |
| Georg Lauer |  | Massachusetts General Hospital and Harvard Medical School | United States | G Lauer_Immune dysfunction vs exhaustion-splitting hairs or real impact on immunotherapy.pdf |
| Massimo Levrero |  | UMR PaThLiv | France | M Levrero_Universal Standards for new HBV biomarkers.pdf |
